FAR HILLS, N.J.--(BUSINESS WIRE)--Samsara Vision, a company focused on bringing vision and freedom back to late-stage, age-related macular degeneration (AMD) patients through advanced visual prosthetic devices, today announced that the German Institute for Hospital Remuneration (InEK) has granted NUB (Neue Untersuchungs- und Behandlungsmethoden) Status 1 reimbursement designation for the SING IMT™ (smaller-incision new-generation implantable miniature telescope).The SING IMT is approved for people living with late-stage, age-related macular degeneration (AMD) who are 55 years of age or older CE Referenced Countries since May 2020.
The NUB process allows negotiations between participating hospitals and health insurance providers regarding supplemental reimbursement of new medical treatments with the potential to improve the standard of care for patients in Germany.
Nearly invisible inside the eye, the tiny SING IMT is a Galilean telescope implant designed to improve visual acuity and quality of life for patients with late-stage, age-related macular degeneration. Comprised of ultra-precision micro-optics, the SING IMT is implanted during typical, out-patient cataract surgery. After recovering from surgery, the patients work closely with a low vision specialist and occupational therapists to learn how to use their new vision.
AMD is the leading cause of blindness in older adults. It is a progressive disease that, for some, will create a blind spot that is uncorrectable by glasses, drugs, injections or cataract surgery. Other currently available treatments for late-stage AMD, such as intraocular injections, may slow or delay the progression of the disease but do not have a direct effect in regaining vision that SING IMT offers to eligible candidates.
“We look forward to working with hospitals and physicians across Germany to offer their patients the most innovative treatment for late-stage AMD,” said Jason Herod, Chief Commercial Officer, Europe, Samsara Vision. “We’ve already established several partnerships and are building our referral network to help bring our novel technology to people who are living with blind spots caused by AMD that restricts their ability to see the people they love and participate in the activities they enjoy. We hope that the SING IMT offers hope to people living with late-stage AMD.”
About SING IMT
Because AMD is a progressive disease, over time, patients have adapted with the loss of vision in the central field of vision. Before receiving the SING IMT, patients must understand the possible and realistic outcomes post-op and commit to working with their ophthalmological team to use visual techniques and exercises to maximize the effectiveness of SING IMT. Patients must also meet age, vision, cornea health, and other requirements noted in the Patient Information Booklet to determine if they are a candidate for the SING IMT.
The telescopic implant is not a cure for late-stage age-related macular degeneration (AMD). It will not return your vision to the level a patient had before AMD, nor will it completely make up for vision loss. The most common risks of the SING IMT surgery include inflammatory deposits or precipitates on the device and increased intraocular pressure. Significant adverse events include corneal edema, vision-impairing corneal edema, corneal transplant, and decrease in visual acuity. There is a risk that having the telescope implantation surgery could worsen your vision rather than improve it. Individual results may vary.
The SING IMT is approved for late-stage AMD patients who are 55 years of age or older CE Referenced Countries and is not currently FDA approved in the United States.
To learn more about SING IMT, visit http://singimt.samsaravision.com
About Samsara Vision
Samsara Vision is a privately held specialty medical device company headquartered in the United States and engaged in the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. We believe that rejuvenating eyesight revives the spirit, allowing people to reconnect to the things in life that they love to see and do. Our approach includes working collaboratively with health care providers, researchers, payers, and advocates to ensure that people living with deteriorating vision have access to our novel technologies and support paths thereby better ensuring a future where they can see anew. Learn more at https://www.samsaravision.com/
Safe Harbor Statement
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. Forward-looking statements include those about the belief that the company’s name change better reflects Samsara’s patient centricity and focus and the belief that rejuvenating eyesight revives the spirit, allowing people to reconnect to the things in life that they love to see and do. These forward-looking statements and their implications are based on the current expectations of the management of Samsara only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: claims by other companies and persons regarding ownership over intellectual property; changes in technology and market requirements; Samsara may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Samsara’s products may not be approved by regulatory agencies, Samsara’s technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Samsara may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Samsara’s process; Samsara’s products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Samsara’s patents may not be sufficient; Samsara’s products may harm recipients; changes in legislation may adversely impact Samsara; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Samsara to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Samsara undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
